ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.